Special Interest Groups (SIG) Member Spotlights
PAIN PAIN Reports Pain Research Forum Events
Online Learning - PERC Curricula Graduate Opportunities Treatment and Education Resources Events
Resources for Living with Pain Topic Pages Events
Support IASP Sponsor an Event Become a Partner Make a Donation
PUBLISHED
26 January 2023
RECENT POSTS
Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and under evaluation for the management of Crohn's disease in phase 3 clinical trials.
